Fintel reports that on January 23, 2025, Piper Sandler initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a ...

Piper Sandler initiated coverage of Bright Minds Biosciences (DRUG) with an Overweight rating and $93 price target The firm believes the ...

Bright Minds Biosciences (DRUG) has received a new Buy rating, initiated by Piper Sandler analyst, Yasmeen Rahimi.Invest with Confidence: ...

HC Wainwright began coverage on shares of Bright Minds Biosciences (NASDAQ:DRUG – Free Report) in a report released on Friday, Marketbeat Ratings reports. The firm issued a buy rating and a $85.00 ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener An announcement ...

Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ...

Analysts at Cantor Fitzgerald initiated coverage on shares of Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) in a note issued to investors on Friday, MarketBeat.com reports.

Bright Minds Biosciences (DRUG) is finishing 2024 as one of the best-performing small-cap stocks, posting a remarkable 2400% increase in the share price in the last quarter. News of the firm’s ...

The average Revenue of companies in the Sector is 663.5 M with a standard deviation of 2.237 B. Bright Minds Biosciences Inc's Revenue of - ranks in the - percentile for the Sector. The following ...

NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company ...